Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Cyclosporin safe, effective for long-term autoimmune hepatitis treatment

30 May 2019
World Hepatitis Day (WHD) takes places every year on 28 July.

Cyclosporin (CSA) is safe and effective for long-term treatment of autoimmune hepatitis (AIH), a recent study has shown.

Researchers retrospectively assessed 20 young patients (median age at diagnosis, 9.5 years; 15 females) of whom 15 had classical AIH and five had AIH/autoimmune sclerosing cholangitis overlap syndrome. Patients were treated with CSA for a median duration of 6.3 years either alone or in combination with mycophenolate mofetil, azathioprine or prednisone.

After a median treatment period of 8.5 weeks, CSA resulted in 100-percent initial clinical and biochemical remission. After 8.6 years of follow-up, all patients were alive and had their native livers. Only one was listed for transplantation.

Of the 12 patients who received CSA as a first-line treatment, 10 reached complete remission at the end of follow-up. Four of these patients had had one or more relapse episodes. In comparison, there was one case each of treatment failure and incomplete response to treatment.

Of the eight patients who received CSA as second-line treatment, five achieved complete remission at the end of follow-up, two had treatment failure, and one had incomplete response.

In terms of safety, researchers reported hypertrichosis in 45 percent (n=9) of the participants, which resolved either spontaneously or after CSA was tapered off. Eleven patients (55 percent) displayed gingival hyperplasia, all cases of which likewise resolved after dosage reduction.

Estimated glomerular filtration rate at the beginning of CSA treatment and at the end of follow-up were statistically comparable (p=0.41), indicating the long-term safety of treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 04 Sep 2019
Use of sodium glucose cotransporter 2 (SGLT2), as compared with dipeptidyl peptidase 4 (DPP4), inhibitors appears to reduce the risk of heart failure and any-cause death without major cardiovascular events in the primary intention-to-treat analysis, according to a study.
Pearl Toh, 04 Sep 2019
More intensive LDL-lowering by adding ezetimibe to simvastatin in elderly individuals aged ≥75 years significantly reduced recurrent cardiovascular (CV) events without raising safety issues compared with simvastatin alone, a secondary analysis of the IMPROVE-IT* has shown.
27 Aug 2019
A once-weekly regimen of 25 mg trelagliptin is effective and safe for type 2 diabetes mellitus (T2DM) patients with severe renal impairment or end-stage renal disease, reports a new study.
Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.